Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
UBS
Daiichi Sankyo
Express Scripts
Queensland Health
McKesson
Merck
Healthtrust
Federal Trade Commission
Farmers Insurance

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,024,981

« Back to Dashboard

Summary for Patent: 6,024,981
Title: Rapidly dissolving robust dosage form
Abstract:The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a non-direct compression filler and a relatively high lubricant content.
Inventor(s): Khankari; Rajendra K. (Maple Grove, MN), Hontz; John (Plymouth, MN), Chastain; Sara J. (Maple Grove, MN), Katzner; Leo (Eden Prairie, MN)
Assignee: Cima Labs Inc. (Eden Prairie, MN)
Application Number:09/057,884
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,024,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-004 May 30, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-001 Feb 10, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-003 Jun 3, 2005 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-002 Feb 10, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-005 Jul 9, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Jazz Pharms Iii FAZACLO ODT clozapine TABLET, ORALLY DISINTEGRATING;ORAL 021590-006 Jul 9, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-001 Sep 24, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-002 Sep 24, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-001 Oct 30, 2003 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-002 Oct 30, 2003 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,024,981

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,221,392 Rapidly dissolving robust dosage form ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,024,981

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 6896998 ➤ Subscribe
Australia 726336 ➤ Subscribe
Canada 2284663 ➤ Subscribe
Denmark 2147669 ➤ Subscribe
Denmark 2266538 ➤ Subscribe
European Patent Office 0975336 ➤ Subscribe
European Patent Office 2147669 ➤ Subscribe
European Patent Office 2266538 ➤ Subscribe
Spain 2525720 ➤ Subscribe
Hong Kong 1137654 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Chubb
Harvard Business School
Citi
Boehringer Ingelheim
Julphar
Colorcon
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot